Login to Your Account

Investors cheering Syros: RARα agonist to phase II in AML, MDS with $40M

By Randy Osborne
Staff Writer

Wednesday, January 13, 2016

A gene control pathway mapper working directly in human disease tissue, Syros Pharmaceuticals Inc. pulled down $40 million by way of its preferred stock transaction to advance SY-1425 (tamibarotene), described as a first-in-class selective agonist to retinoic acid receptor alpha (RARα), into a phase II trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription